These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 32192503)
41. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study. Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543 [TBL] [Abstract][Full Text] [Related]
42. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists. Bonaventura A; Carbone S; Dixon DL; Abbate A; Montecucco F J Intern Med; 2019 Jul; 286(1):16-31. PubMed ID: 30888088 [TBL] [Abstract][Full Text] [Related]
43. Cardiovascular Outcomes With the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials. Malik AH; Yandrapalli S; Goldberg M; Jain D; Frishman WH; Aronow WS Cardiol Rev; 2020; 28(3):116-124. PubMed ID: 31868769 [TBL] [Abstract][Full Text] [Related]
44. Sodium-Glucose Cotransporter-2 Inhibitors and Protection Against stroke in Patients with type 2 Diabetes and Impaired Renal Function: A Systematic Review and Meta-Analysis. Barkas F; Ntekouan SF; Liberopoulos E; Filippatos T; Milionis H J Stroke Cerebrovasc Dis; 2021 May; 30(5):105708. PubMed ID: 33714073 [TBL] [Abstract][Full Text] [Related]
45. Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease? Rajasekeran H; Cherney DZ; Lovshin JA Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):358-367. PubMed ID: 28582367 [TBL] [Abstract][Full Text] [Related]
47. Mechanisms for Cardiorenal Protection of SGLT-2 Inhibitors. Georgianos PI; Vaios V; Dounousi E; Salmas M; Eleftheriadis T; Liakopoulos V Curr Pharm Des; 2021; 27(8):1043-1050. PubMed ID: 33463454 [TBL] [Abstract][Full Text] [Related]
48. Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease. Dai ZC; Chen JX; Zou R; Liang XB; Tang JX; Yao CW Front Immunol; 2023; 14():1213473. PubMed ID: 37809091 [TBL] [Abstract][Full Text] [Related]
49. Do we have enough evidence to support the use of SGLT2 inhibitors for MACE reduction in patients with advance kidney disease? Doshi R; Meghji Z; Kumar A; Shariff M; Adalja D Eur J Intern Med; 2019 Dec; 70():e25-e26. PubMed ID: 31685351 [No Abstract] [Full Text] [Related]
50. Inhibition of the Sodium-Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2. McCullough PA; Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Kluger SL; Rangaswami J Rev Cardiovasc Med; 2018 Jun; 19(2):51-63. PubMed ID: 31032603 [TBL] [Abstract][Full Text] [Related]
51. Management of type 2 diabetes in chronic kidney disease. Triozzi JL; Parker Gregg L; Virani SS; Navaneethan SD BMJ Open Diabetes Res Care; 2021 Jul; 9(1):. PubMed ID: 34312158 [TBL] [Abstract][Full Text] [Related]
52. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085 [TBL] [Abstract][Full Text] [Related]
53. Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry. Wittbrodt E; Chamberlain D; Arnold SV; Tang F; Kosiborod M Diabetes Obes Metab; 2019 Aug; 21(8):1985-1989. PubMed ID: 30968543 [TBL] [Abstract][Full Text] [Related]
54. Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: Impact of the 2020 KDIGO clinical practice guidelines. Ciardullo S; Trevisan R; Perseghin G Pharmacol Res; 2021 Apr; 166():105530. PubMed ID: 33675963 [TBL] [Abstract][Full Text] [Related]
55. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892 [TBL] [Abstract][Full Text] [Related]